Literature DB >> 8875189

The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.

T Peelen1, R S Cornelis, M van Vliet, A Petrij-Bosch, A M Cleton-Jansen, H Meijers-Heijboer, J G Klijn, H F Vasen, C J Cornelisse, P Devilee.   

Abstract

We have analyzed, by a combination of mutation and linkage analysis, the genetic basis of 22 breast cancer families in which at least 4 cases of either breast cancer diagnosed under the age of 60 or ovarian cancer had occurred. Chain-terminating mutations in BRCA1 were evidenced in 6 families, and posterior probabilities of > 0.90 of being linked to BRCA1 in 3. The breast versus ovarian cancer ratio in these 9 families was approximately 2:1. Among the remaining 13 families, significant linkage to markers flanking BRCA2 was established in the admixture test with a maximum multipoint lod score of 3.38, but there was no statistical evidence for genetic heterogeneity. The breast:ovarian cancer ratio in these families was 7:1, suggesting BRCA2 confers a much lower risk for ovarian cancer than does BRCA1. These results suggest that BRCA2 will explain a significant proportion of hereditary breast cancer in the Netherlands, and, together with BRCA1, account for the majority of all high-risk families.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875189     DOI: 10.1159/000472203

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  5 in total

Review 1.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

2.  BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.

Authors:  D Stoppa-Lyonnet; P Laurent-Puig; L Essioux; S Pagès; G Ithier; L Ligot; A Fourquet; R J Salmon; K B Clough; P Pouillart; C Bonaïti-Pellié; G Thomas
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

3.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Petrij-Bosch; R Mieremet; C Szabo; A M van den Ouweland; F Hogervorst; R Brohet; M J Ligtenberg; E Teugels; R van der Luijt; A H van der Hout; J J Gille; G Pals; I Jedema; R Olmer; I van Leeuwen; B Newman; M Plandsoen; M van der Est; G Brink; S Hageman; P J Arts; M M Bakker; P Devilee
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.

Authors:  J Chang-Claude; J Dong; S Schmidt; M Shayeghi; D Komitowski; H Becher; M R Stratton; B Royer-Pokora
Journal:  J Med Genet       Date:  1998-02       Impact factor: 6.318

5.  Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Bosch; G Bignell; H F Vasen; J G Klijn; H Meijers-Heijboer; M Stratton; G J van Ommen; C J Cornelisse; P Devilee
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.